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Introduction
Various risk factors have been associated with an increased risk for Alzheimer's disease (AD) (Breteler, 2000; de Bruijn and Ikram, 2014) . Recently, research criteria have been proposed to identify AD in subjects with mild cognitive impairment (MCI) by their biomarker status, referred to as prodromal AD by international working group-2 (IWG-2) (Dubois, et al., 2014) and MCI due to AD by the National Institute of Aging-Alzheimer Association (NIA-AA) (Albert, et al., 2011) . It remains uncertain whether risk factors are associated with prodromal AD/ MCI due to AD, and whether they influence the rate of cognitive decline. This information could improve early diagnosis and lead to new targets for secondary prevention strategies.
Among the best-validated risk factors for AD are atherosclerosis, depression, diabetes mellitus, hypercholesterolemia, hypertension, lacunar infarcts, stroke, obesity, smoking, and alcohol consumption (Breteler, 2000; de Bruijn and Ikram, 2014; Deckers, et al., 2015) . Diabetes mellitus, depression, hypertension, stroke and cardiovascular diseases have also been associated with an increased risk of progressing from cognitively normal to MCI (Pankratz, et al., 2015; Roberts, et al., 2015) . Moreover, an association with cognitive decline has been found in both cognitively normal and MCI subjects (Jefferson, et al., 2015; Kaffashian, et al., 2013) .
Therefore, we hypothesize that risk factors will occur more frequently in individuals with prodromal AD/MCI due to AD. We also expect that risk factors will increase the risk of progression to dementia.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT

6
We aim to investigate the frequency of several risk factors in individuals with prodromal AD/MCI due to AD, classified according to the IWG-2 and NIA-AA criteria, relative to subjects who do not meet these criteria. Secondly, we aim to examine whether risk factors influence the rate of cognitive decline.
Methods
Subjects
Subjects were recruited from five multicenter memory-clinic based studies:
DESCRIPA (Visser, et al., 2008) , German Dementia Competence Network (DCN) (Kornhuber, et al., 2009) , EDAR (www.edarstudy.eu), the European Alzheimer's Disease Consortium (EADC)-PET study (Morbelli, et al., 2012) and American
Alzheimer's Disease Neuroimaging Initiative (ADNI-1) study (Mueller, et al., 2005) ;
and nine centers of the EADC and/or European Medical Information Framework (EMIF)-AD: Amsterdam (van der Flier, et al., 2014) , Antwerp (Somers C., In press), Barcelona (Alcolea, et al., 2014) , Brescia (Frisoni, et al., 2009) , Coimbra (Baldeiras, et al., 2008) , Gothenburg (Wallin, et al., 2016) , Kuopio (Seppala, et al., 2011) , Liège (Bastin, et al., 2010) and Lisbon (Maroco, et al., 2011) . For subjects who participated in more than one study, we used data from the study with the longest follow-up.
Inclusion criteria consisted of baseline diagnosis of MCI according to the criteria of Petersen (Petersen, 2004) , and at least one of the following biomarkers available at baseline: amyloid-beta (Aβ) 1-42 and tau (total tau and/or phosphorylated tau) in CSF, hippocampal volume on magnetic resonance imaging (MRI) or cerebral glucose metabolism on [18F]FDG-PET of the brain. Moreover, baseline data had to be available on at least one of the selected risk factors, as well as information on M A N U S C R I P T
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Clinical assessment
The clinical assessment is described in detail by Vos et al. (Vos, et al., 2015) . In short,
clinical assessment was performed at each site according to local routine protocol.
Cognitive impairment was defined as Z-score < -1.5 SD on at least one neuropsychological test, which could be a memory or non-memory test.
Outcome at follow-up
Cognitive decline was defined as progression to dementia according to the Diagnostic (McKhann, et al., 1984) .
The medical ethics committee at each site approved the study. All subjects provided informed consent.
Biomarker assessment
Biomarker assessment was performed according to the routine protocol at each site and center-specific cut-offs were used to define abnormality, as described elsewhere Vos, et al., 2015) . Examination of medial temporal lobe atrophy on MRI and cerebral glucose metabolism on FDG-PET were performed through visual assessment.
Subject classification
Subjects were classified as having prodromal AD according to the IWG-2 criteria using CSF Aβ1-42 and tau biomarkers ( Table 1 ). The NIA-AA criteria distinguish between six groups that indicate the likelihood that MCI is due to AD, based on combinations of amyloid and neuronal injury markers. We used CSF Aβ1-42 as amyloid marker and CSF total tau, CSF phosphorylated tau, cerebral glucose metabolism on FDG-PET, hippocampal volume or medial temporal lobe atrophy on MRI as neuronal injury markers (Table 1 ).
Risk factors
We assessed the following risk factors at baseline: atherosclerotic disease, depression, diabetes, hypercholesterolemia, hypertension, lacunar infarct, obesity, stroke, current smoking, and current alcohol use. Not all risk factors were available for each subject.
Supplemental Table 1 provides an overview of the available risk factors for each center. The risk factor definitions are described by center in Supplemental Table 2 .
For all risk factors occurrence in medical history was used as a standard. For some risk factors, we used additional definitions based on rating scales, physical measurements or medication use, based on availability (Supplemental Table 2 ).
Statistical analyses
Baseline differences between the biomarker profile groups were analyzed using ANOVA for continuous variables and Chi-Square test for categorical variables. The
relation of risk factors with prodromal AD/MCI due to AD was tested with logistic regression (IWG-2 criteria) or multinomial regression (NIA-AA criteria). Cox proportional hazards models were used to test the effect of each risk factor on the rate of cognitive decline in the total sample, and for the IWG-2 and NIA-AA biomarker subgroups. All analyses were adjusted for age, sex, education and center. Statistical analyses were performed using SPSS version 22.0 with the significance level set at p<0.05. We corrected for multiple comparisons, using the false discovery rate (FDR) adjustment (Benjamini and Hochberg, 1995) , taking into account the testing of ten risk factors. In tables, we reported uncorrected p-values and we indicated which associations were significant after correction for multiple comparisons in tables and the text.
Results
Subject characteristics
We included 1394 individuals (mean age = 69.7, SD 8.3; 51% female). Seven hundred and fifty-eight subjects had data available on both amyloid and neuronal injury markers, while 636 subjects only had data on a neuronal injury marker (medial temporal lobe atrophy n=528, FDG-PET n=108). Five hundred and eighty individuals (42%) showed cognitive decline after an average follow-up time of 2.3 (SD 1.2) years. Table 2 shows the characteristics of the subjects classified according to the IWG-2 and the NIA-AA criteria.
Analyses in subjects with both amyloid and neuronal injury markers
Based on the IWG-2 criteria, 302 subjects (40%) were classified as prodromal AD.
Individuals with prodromal AD were older (p<0.001), showed a lower score on the M A N U S C R I P T
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10 MMSE at follow-up (p<0.001) and were more likely to progress to AD-type dementia at follow-up (p<0.001) compared to subjects without prodromal AD. According to the NIA-AA criteria, 142 individuals (10%) were classified in the low-AD-likelihood group, 356 (26%) in the high-AD-likelihood group, 54 (4%) in the Isolated Amyloid Pathology (IAP) group, and 206 (15%) in the Suspected Non-AD Pathophysiology (SNAP) group. Subjects in the high-AD-likelihood group were older and most likely to progress to AD-type dementia, compared to all other groups (Table 2) . Table 3 shows the frequency of AD risk factors for the NIA-AA groups with both amyloid and neuronal injury data. Compared to the high-AD-likelihood group, subjects in the low-AD-likelihood group had a higher frequency of depression (46% vs. 17%, p=0.004, FDR p=0.020), obesity (21% vs. 8%, p=0.004, FDR p=0.020) and hypercholesterolemia (43% vs. 27%, p=0.009, FDR p=0.030). No differences were found between the groups for the other risk factors (Table 3 ).
Frequency of risk factors
Supplemental Table 3 shows the frequency of risk factors for the groups according to the IWG-2 criteria. In the group without prodromal AD we found higher frequencies of depression (34% vs. 16%, p=0.009, FDR p=0.045) and obesity (17% vs. 8%, p=0.007, FDR p=0.045) compared to the group with prodromal AD (Supplemental Table 3 ).
Effect of risk factors on cognitive decline
In the total group of subjects with both amyloid and neuronal injury markers, alcohol use was associated with a higher risk of cognitive decline (HR=1.5, p=0.003, FDR Table 4 ). There were no significant interactions between risk factors and NIA-AA group classification, indicating that the effect of risk factors was similar for all groups. Using the IWG-2 classification, the effects of depression, hypercholesterolemia, and smoking were different between the two groups, but these differences were no longer statistical significant after adjusting for multiple testing (Table 4) . Table 4 ).
Analyses in subjects with only neuronal injury markers
In the subjects with only neuronal injury markers available, none of the risk factors increased the risk of cognitive decline. Also, there was no difference between the two NIA-AA groups in the rate of cognitive decline (Supplemental Table 5 ).
Post-hoc analyses -progression to AD-type dementia
When we repeated the analyses with only progression to AD-type dementia as an outcome in subjects with both amyloid and neuronal injury markers available (n=725), alcohol use was no longer associated with an increased risk of progression (HR=1.3, 95% CI: 0.9 -1.8, p=0.164).
Since the ADNI cohort excluded subjects with depressive symptoms (GDS>6), we repeated the analyses concerning depression without ADNI subjects. This did not influence the results.
Discussion
We examined the frequency of vascular and lifestyle risk factors in prodromal AD/MCI due to AD, and the influence of these factors on cognitive decline, in subjects with MCI. We found that the frequencies of depression, hypercholesterolemia and obesity were higher in the group without AD pathology compared to the group with AD pathology. Only alcohol increased the risk of cognitive decline, regardless of AD-pathology.
Frequency of risk factors
Contrary to our hypothesis we found higher frequencies of depression, hypercholesterolemia and obesity, in the group without prodromal AD and in the low-AD-likelihood group. This suggests that subjects without prodromal AD or low-ADlikelihood had cognitive impairment due to other causes than AD, such as depression or vascular disorders (DeCarli, 2003; Gorelick, et al., 2011) . It is also possible that low cholesterol or low body mass index are risk factors for prodromal AD in this elderly sample. While obesity and hypercholesterolemia in middle age have been
shown to be predictive for AD (Deckers, et al., 2015; Kivipelto, et al., 2005) , other studies showed that this association is reversed at older age, such that low body mass index and low cholesterol increase the risk for AD (Anstey, et al., 2008; Johnson, et al., 2006) . When we compared the frequencies observed in the current study to the prevalence of risk factors reported in meta-analyses and population-based cohort studies (Supplemental Table 6 ), we found that the frequencies of obesity and hypercholesterolemia in the high-AD-likelihood group were decreased, while frequencies were similar in subjects with a low-AD-likelihood. On the contrary, the frequency of depression in the high-AD-likelihood group was similar to that in the general population while it was higher in the low-AD-likelihood group compared to the population-based studies. This would suggest that the difference in frequencies of obesity and hypercholesterolemia between the low and high-AD-likelihood in our study results from a decrease of obesity and hypercholesterolemia in the high-ADlikelihood, rather than from an increase in the low-AD-likelihood. Conversely, the difference in frequency in depression between groups could result from an increase in frequency of depression in the low-AD-likelihood. This indicates that depression can be a possible cause of MCI in the studied population (DeCarli, 2003; Defrancesco, et al., 2009) . Clearly there are methodological differences in the inclusion of subjects, definition and method of ascertainment of risk factors and age range between the current study and the population based studies. Studies that directly compare frequency of risk factors in prodromal AD to cognitively normal subjects are needed to further clarify this.
Influence of risk factors on cognitive decline
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Alcohol consumption was associated with an increased risk of cognitive decline, independent of AD-pathology. Although this finding is in line with several previous studies (Deckers, et al., 2015; Jauhar, et al., 2014) that identified alcohol as a risk factor for cognitive decline, other studies have reported a protective or no relation to alcohol consumption with incident AD (Anstey, et al., 2009; Ruitenberg, et al., 2002) .
These conflicting results could be explained by differences in study population (MCI versus cognitively normal), definitions of alcohol consumption (dichotomous versus categories based on the amount of alcohol use) and the type of alcohol. When conversion to AD-type dementia was used as outcome instead of conversion to dementia or a decline on the MMSE, we found that the effect of alcohol was no longer significant. This suggests that alcohol consumption mainly has an effect on progression to non-AD types of dementia or cognitive decline in general.
IWG-2 vs. NIA-AA criteria
The results on frequency of risk factors were comparable for the IWG-2 and NIA-AA criteria. Also, when comparing the effect of risk factors on cognitive decline we found similar outcomes when using the two sets of criteria. This shows that although the IWG-2 criteria only classify neuronal injury based on tau in CSF and the NIA-AA criteria also include other neuronal injury markers, this did not influence the results.
Although the outcomes were similar for the two sets of criteria, the NIA-AA criteria provided more insight into which specific biomarker profile was associated with a higher frequency of a certain risk factor, which could be useful to give a more refined diagnosis and prognosis of early AD and age-related comorbidities.
Strengths and limitations of the study
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Strengths of the study are the large sample size, the broad spectrum of assessed risk factors and longitudinal data on clinical outcome. There are also limitations to this study that should be mentioned. Some of the biomarker subgroups were small and some risk factors were only available in a subgroup or had a low frequency, which limited statistical power. The data used in this study was contributed by different centers and data was not collected using the same protocol. This might have led to variability, although it does reflect current clinical practice. Furthermore, the use of indirect measures (e.g. medical history) of risk factors could have introduced heterogeneity in classification. We were unable to study the potential interactions between risk factors, as not all centers contributed data on all risk factors. We had only limited data available on medication use, which did not allow us to control for this. Also, we could not correct for the duration and the severity of a risk factor, as we had no information on this. Although the mean follow-up was 2.3 years, some individuals likely would have shown cognitive decline at a later stage. Since these findings are based on clinical research populations, they may not be generalizable to other settings.
Conclusion
In summary, we found that dementia risk factors were not associated with prodromal AD/MCI due to AD in subjects with MCI, and only alcohol increased the risk of cognitive decline, regardless of underlying pathology. Moreover, we found that a lower frequency of hypercholesterolemia or obesity may be indicative of early AD in an elderly population. Although our findings should be validated in future studies, Decline on MMSE at follow-up was defined as a difference of 3 points or more and was available in a subgroup of the samples: IWG-2 no prodromal AD n=237, prodromal AD n=223; NIA-AA M A N U S C R I P T 
